EE04877B1 - Asendatud 3-fenl-5-alkoks-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi p„rssivas ravimis ning seda sisaldav suhkurt?ve ravim - Google Patents

Asendatud 3-fenl-5-alkoks-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi p„rssivas ravimis ning seda sisaldav suhkurt?ve ravim

Info

Publication number
EE04877B1
EE04877B1 EEP200200498A EEP200200498A EE04877B1 EE 04877 B1 EE04877 B1 EE 04877B1 EE P200200498 A EEP200200498 A EE P200200498A EE P200200498 A EEP200200498 A EE P200200498A EE 04877 B1 EE04877 B1 EE 04877B1
Authority
EE
Estonia
Prior art keywords
suppressant
oxadiazol
hormone
alkoxy
sugar
Prior art date
Application number
EEP200200498A
Other languages
English (en)
Estonian (et)
Inventor
Schoenafinger Karl
Petry Stefan
Mueller Guenter
Baringhaus Karl-Heinz
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000110968 external-priority patent/DE10010968A1/de
Priority claimed from DE2001102265 external-priority patent/DE10102265C1/de
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of EE200200498A publication Critical patent/EE200200498A/xx
Publication of EE04877B1 publication Critical patent/EE04877B1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/1131,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
EEP200200498A 2000-03-07 2001-02-20 Asendatud 3-fenl-5-alkoks-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi p„rssivas ravimis ning seda sisaldav suhkurt?ve ravim EE04877B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000110968 DE10010968A1 (de) 2000-03-07 2000-03-07 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE2001102265 DE10102265C1 (de) 2001-01-18 2001-01-18 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
PCT/EP2001/001898 WO2001066531A1 (de) 2000-03-07 2001-02-20 Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one (und) ihre verwendung zur hemmung der hormonsensitiven lipase

Publications (2)

Publication Number Publication Date
EE200200498A EE200200498A (et) 2004-02-16
EE04877B1 true EE04877B1 (et) 2007-08-15

Family

ID=26004720

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200498A EE04877B1 (et) 2000-03-07 2001-02-20 Asendatud 3-fenl-5-alkoks-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi p„rssivas ravimis ning seda sisaldav suhkurt?ve ravim

Country Status (28)

Country Link
US (1) US6369088B2 (ko)
EP (1) EP1263745B1 (ko)
JP (1) JP2003525931A (ko)
KR (1) KR100790763B1 (ko)
CN (1) CN1261419C (ko)
AR (1) AR027611A1 (ko)
AT (1) ATE267184T1 (ko)
AU (1) AU784827B2 (ko)
BR (1) BR0108974A (ko)
CA (1) CA2401953A1 (ko)
DE (1) DE50102325D1 (ko)
DK (1) DK1263745T3 (ko)
EE (1) EE04877B1 (ko)
ES (1) ES2218383T3 (ko)
HK (1) HK1054036B (ko)
HR (1) HRP20020732A2 (ko)
HU (1) HUP0302772A3 (ko)
IL (1) IL151518A (ko)
MX (1) MXPA02008038A (ko)
NO (1) NO323483B1 (ko)
NZ (1) NZ521207A (ko)
PL (1) PL359702A1 (ko)
PT (1) PT1263745E (ko)
RU (1) RU2281283C2 (ko)
SK (1) SK12752002A3 (ko)
TR (1) TR200401217T4 (ko)
WO (1) WO2001066531A1 (ko)
YU (1) YU57802A (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6900233B2 (en) 2002-02-28 2005-05-31 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
DE10208987A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
TW201033163A (en) * 2008-10-20 2010-09-16 Sumitomo Chemical Co Method for manufacturing oxadiazolinone compound and intermediate thereof
TW201028406A (en) 2008-12-23 2010-08-01 Bial Portela & Ca Sa 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use
WO2011108724A1 (ja) 2010-03-04 2011-09-09 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JP6007417B2 (ja) * 2011-05-31 2016-10-12 レセプトス エルエルシー 新規glp−1受容体安定剤および調節剤
AU2012352349B2 (en) 2011-12-12 2017-08-17 Receptos Llc Carboxylic acid derivatives comprising four cycles acting as GLP-1 receptor modulators for therapy of diseases such as diabetes
KR102271179B1 (ko) 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
MX2017000972A (es) 2014-07-25 2017-07-27 Celgene Int Ii Sarl Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
WO2016094729A1 (en) 2014-12-10 2016-06-16 Celgene International Ii Sarl Glp-1 receptor modulators
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108863774A (zh) * 2018-06-09 2018-11-23 石家庄市绿丰化工有限公司 一种2,4-二氯苯乙酰氯合成的方法
CN113227093A (zh) 2018-11-14 2021-08-06 阿尔塔万特科学公司 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2299328A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Derives de l'alcoyloxy-5 phenyl-3 oxyde azo
US4076824A (en) 1975-02-03 1978-02-28 Rhone-Poulenc Industries Anthelmintic oxadiazolinone derivatives
FR2299028A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Nouvea
DK156439C (da) 1980-09-15 1990-01-22 Shell Int Research 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer
DE3267258D1 (en) 1981-06-15 1985-12-12 Shell Int Research 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates
US5236939A (en) 1989-09-23 1993-08-17 Bayer Aktiengesellschaft Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
DE3931843A1 (de) 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Also Published As

Publication number Publication date
PT1263745E (pt) 2004-09-30
NO20024201D0 (no) 2002-09-03
MXPA02008038A (es) 2004-04-05
WO2001066531A1 (de) 2001-09-13
TR200401217T4 (tr) 2004-06-21
CN1416424A (zh) 2003-05-07
RU2281283C2 (ru) 2006-08-10
JP2003525931A (ja) 2003-09-02
AU784827B2 (en) 2006-06-29
BR0108974A (pt) 2003-06-03
ATE267184T1 (de) 2004-06-15
KR100790763B1 (ko) 2008-01-03
CN1261419C (zh) 2006-06-28
AR027611A1 (es) 2003-04-02
AU3378701A (en) 2001-09-17
EP1263745B1 (de) 2004-05-19
IL151518A0 (en) 2003-04-10
DE50102325D1 (de) 2004-06-24
NO20024201L (no) 2002-09-03
US20010031772A1 (en) 2001-10-18
HUP0302772A2 (hu) 2003-11-28
SK12752002A3 (sk) 2003-04-01
PL359702A1 (en) 2004-09-06
IL151518A (en) 2008-06-05
EP1263745A1 (de) 2002-12-11
US6369088B2 (en) 2002-04-09
NZ521207A (en) 2005-04-29
KR20020079986A (ko) 2002-10-21
HK1054036A1 (en) 2003-11-14
NO323483B1 (no) 2007-05-21
WO2001066531A8 (de) 2002-07-25
ES2218383T3 (es) 2004-11-16
YU57802A (sh) 2005-07-19
HRP20020732A2 (en) 2004-12-31
CA2401953A1 (en) 2001-09-13
EE200200498A (et) 2004-02-16
HUP0302772A3 (en) 2007-03-28
HK1054036B (zh) 2006-11-17
DK1263745T3 (da) 2004-08-16

Similar Documents

Publication Publication Date Title
EE04877B1 (et) Asendatud 3-fenl-5-alkoks-1,3,4-oksadiasol-2-oon, selle valmistamine ja kasutamine hormoontundlikku lipaasi p„rssivas ravimis ning seda sisaldav suhkurt?ve ravim
AU2002241538A1 (en) Intrasvascular drug delivery device and use therefor
DK1145711T3 (da) Hurtig smeltende oral dosisformulering
AU3403201A (en) Drug delivery device and method
AU2001270300A1 (en) Drug delivery formulations and targeting
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
AU6275601A (en) Stable polymeric micelle-type drug composition and method for the preparation thereof
EE200300240A (et) Arüülitud furaan- ja tiofeenkarboksamiid, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks
EE200300171A (et) Kristalliline monohüdraat, meetodid selle valmistamiseks ja selle kasutamine farmatseutilise kompositsiooni valmistamiseks
MXPA03005923A (es) Derivados de glupopiranosiloxipirazol y su uso en medicinas.
EE05391B1 (et) Kompositsioon ja vahend selle transdermaalseks manustamiseks
AU2002339993A1 (en) P-amidobenzylethers in drug delivery agents
DZ3313A1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
EE05220B1 (et) Bis-arüülühend, seda sisaldav ravimpreparaat ning ühendi kasutamine kaaliumikanali blokaatorina toimiva ravimi valmistamiseks
EE200200046A (et) 8-fenüül-6,9-dihüdro-[1,2,4]triasolo[3,4-i]puriin-5-ooni derivaat, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon
PT1309317E (pt) Formulacoes farmaceuticas contendo maleato de amlodipina
EE05082B1 (et) Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
DK200300344U1 (da) Amlodipinmaleat og farmaceutisk præparat indeholdende amlodipinmaleat
EE04955B1 (et) Peroraalselt v?i paikselt manustatav farmatseutiline preparaat ja selle ravimvorm
AU2001235442A1 (en) Oral delivery of allergens in milk
EE200200493A (et) Lipiidne kandesüsteem, selle kasutamine ravimpreparaatide valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
EE04811B1 (et) Asendatud 3-fenüül-5-alkoksü-1,3,4-oksdiasool-2-oon, selle valmistamine ja kasutamine lipaasi inhibiitorina ning seda sisaldav ravim
AU2002218502A1 (en) Lactam compounds and medicinal use thereof
NO20035581D0 (no) Farmasöytisk formulering med maskert smak samt fremstilling derav
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090220